Guardant360 CDx assay is the first liquid biopsy companion diagnostic test that uses next-generation sequencing technology to receive FDA approval. The assay uses NGS technology to identify patients with specific types of mutations of the epidermal growth factor receptor gene in a deadly form of metastatic non-small cell lung cancer.
The Cancer Letter’s summer reading list is here and it’s full of titles to help you drive professional growth, reflect on a divided nation—and even explore a little “neural nostalgia” with Beyoncé.
